Cmin公司
基于生理学的药代动力学模型
药代动力学
尼罗替尼
加药
最大值
药理学
医学
养生
内科学
髓系白血病
伊马替尼
作者
Tycho Heimbach,Wen Yu Lin,Florence Hourcade‐Potelleret,Xianbin Tian,François Pierre Combes,Nicholas Horvath,Handan He
标识
DOI:10.1016/j.xphs.2019.01.028
摘要
In adult patients, nilotinib is indicated for chronic myeloid leukemia at an approved oral dose of 300 or 400 mg BID. Physiologically based pharmacokinetic (PBPK) model was developed to describe and supplement limited PK data in the pediatric population ranging from 2 to less than 6 years of age and ultimately inform dosing regimen. An adult Simcyp PBPK model was established and verified with clinical pharmacokinetic data after a single or multiple oral doses of 400 mg nilotinib (230 mg/m2). The model was then applied to a pediatric PBPK model, taking account of ontogeny profiles of metabolizing enzymes and pediatric physiological parameters. The model was further verified using observed pediatric PK data in 12- to <18-year-old and from 6- to <12-year-old patients. The PBPK models were able to recover, describe, and supplement the limited nilotinib concentration-time data profile in 2- to <6-year-old patients after a single dose and Cmin,ss after BID dosing. The exposure (Cmax,ss, Cmin,ss, and AUCtau,ss) was predicted to be similar across age groups. PBPK model simulations confirmed that body surface area-normalized dosing regimen of 230 mg/m2 is considered appropriate for pediatric patients >2 to <18 years of age.
科研通智能强力驱动
Strongly Powered by AbleSci AI